Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
adaptive immunity
glyco-engineered antibody
immunotherapy
murlentamab
ovarian cancer
tumor-associated macrophages
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
14
02
2021
revised:
19
03
2021
accepted:
07
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
AMHRII, the anti-Müllerian hormone receptor, is selectively expressed in normal sexual organs but is also re-expressed in gynecologic cancers. Hence, we developed murlentamab, a humanized glyco-engineered anti-AMHRII monoclonal antibody currently in clinical trial. Low-fucosylated antibodies are known to increase the antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) potency of effector cells, but some preliminary results suggest a more global murlentamab-dependent activation of the immune system. In this context, we demonstrate here that the murlentamab opsonization of AMHRII-expressing ovarian tumor cells, in the presence of unstimulated- or tumor-associated macrophage (TAM)-like macrophages, significantly promotes macrophage-mediated ADCC and shifts the whole microenvironment towards a pro-inflammatory and anti-tumoral status, thus triggering anti-tumor activity. We also report that murlentamab orients both unstimulated- and TAM-like macrophages to an M1-like phenotype characterized by a strong expression of co-stimulation markers, pro-inflammatory cytokines and chemokines, favoring T cell recruitment and activation. Moreover, we show that murlentamab treatment shifts CD4
Identifiants
pubmed: 33924378
pii: cancers13081845
doi: 10.3390/cancers13081845
pmc: PMC8070390
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Future Oncol. 2019 Nov;15(31):3565-3578
pubmed: 31538821
Mol Cell. 2020 Jan 16;77(2):213-227.e5
pubmed: 31735641
Eur J Cancer. 2014 Feb;50(3):496-505
pubmed: 24262587
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Cancer Res. 2008 Oct 1;68(19):8049-57
pubmed: 18829563
Cell Death Differ. 2015 Feb;22(2):237-46
pubmed: 25190142
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
Oncotarget. 2017 Sep 28;8(52):89998-90012
pubmed: 29163806
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752088
Cancer Res. 2004 Mar 15;64(6):2127-33
pubmed: 15026353
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Lab Invest. 2011 Nov;91(11):1605-14
pubmed: 21808236
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Mol Cell Endocrinol. 2003 Dec 15;211(1-2):15-9
pubmed: 14656471
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Nature. 2016 Nov 17;539(7629):443-447
pubmed: 27828943
FEBS J. 2018 Feb;285(4):680-699
pubmed: 29171156
Immunol Rev. 1998 Jun;163:59-76
pubmed: 9700502
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
MAbs. 2014;6(5):1314-26
pubmed: 25517316
Ann Oncol. 2017 Nov 1;28(11):2827-2835
pubmed: 28950289
J Mol Cell Biol. 2020 Apr 24;12(3):202-215
pubmed: 31504643
Blood. 2019 Nov 14;134(20):1691-1696
pubmed: 31488409
Mol Hum Reprod. 2000 Feb;6(2):146-53
pubmed: 10655456
Mol Endocrinol. 1994 Aug;8(8):1006-20
pubmed: 7997230
J Androl. 2001 Sep-Oct;22(5):750-8
pubmed: 11545286
Blood. 2007 Dec 15;110(13):4319-30
pubmed: 17848619
J Biol Chem. 2003 Jan 31;278(5):3466-73
pubmed: 12427744
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
J Exp Med. 2004 Jun 21;199(12):1659-69
pubmed: 15210744
Nat Rev Endocrinol. 2012 Jan 10;8(6):331-41
pubmed: 22231848
Nat Rev Drug Discov. 2017 Jun 29;16(7):455
pubmed: 28660900
Nat Rev Immunol. 2020 Oct;20(10):633-643
pubmed: 32782358
Cancer Res. 2018 Sep 1;78(17):4929-4942
pubmed: 29967265
J Immunol. 2014 Mar 1;192(5):2252-60
pubmed: 24489098
Clin Cancer Res. 2020 Jan 15;26(2):487-504
pubmed: 31636098
J Transl Med. 2011 Dec 16;9:216
pubmed: 22176642
Oncotarget. 2017 Oct 7;8(59):99950-99965
pubmed: 29245952
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109
pubmed: 11900986
J Biol Chem. 2002 Jul 26;277(30):26733-40
pubmed: 11986321
Gynecol Oncol. 2008 Jan;108(1):141-8
pubmed: 17988723
J Clin Oncol. 2011 Oct 1;29(28):3783-90
pubmed: 21900113
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4418-27
pubmed: 26216943
Oncotarget. 2017 Jun 6;8(23):37061-37079
pubmed: 28427157
Development. 1994 Jan;120(1):189-97
pubmed: 8119126
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32503947
Front Immunol. 2019 Jul 31;10:1799
pubmed: 31417566
Cell Rep. 2016 Jul 19;16(3):657-71
pubmed: 27396341
Clin Cancer Res. 2010 Apr 15;16(8):2352-62
pubmed: 20371695
Int J Oncol. 2009 Jun;34(6):1583-91
pubmed: 19424576